Mast cells and inflammatory heart disease: Potential drug targets

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 1, 2008, Pages 80-90

  Fairweather, DeLisa ^a,b   Frisancho Kiss, Sylvia ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Fibrosis; Inflammation; Mast cells; Myocarditis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; B7 ANTIGEN; CARDIOVASCULAR AGENT; CD86 ANTIGEN; CHYMASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HISTAMINE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; AUTACOID; CYTOKINE;

ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; B LYMPHOCYTE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; COXSACKIE VIRUS B3; DRUG TARGETING; ENZYME REGULATION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MAST CELL; MAST CELL DEGRANULATION; MYOCARDITIS; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; DEGRANULATION; FIBROSIS; HEART DISEASE; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL DEGRANULATION; CYTOKINES; FIBROSIS; HEART DISEASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MAST CELLS; MYOCARDIUM;

EID: 43649088631     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908783884957     Document Type: Review

References (131)

1. Galli, S.J.; Nakae, S.; Tsai, M. Mast cells in the development of adaptive immune responses. Nature Immunol., 2005, 6, 135-142.
2. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-1143.
3. Ayach, B.; Fuse, K.; Marino, T.; Liu, P. Dissecting mechanisms of innate and acquired immunity in myocarditis. Curr. Opin. Cardiol., 2003, 18, 175-181.
4. Wick, G.; Knoflach, M.; Xu, Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu. Rev. Immunol., 2004, 22, 362-403.
5. Michelsen, K.S.; Arditi, M. Toll-like receptor signaling and atherosclerosis. Curr. Opin. Hematol., 2006, 13, 163-168.
6. Mitra, A.K.; Del Core, M.G.; Agrawal, D.K. Cells, cytokines and cellular immunity in the pathogenesis of fibroproliferative vasculopathies. Can. J. Physiol. Pharmacol., 2005, 83, 701-715.
7. Kaartmen, M.; Penttila, A.; Kovanen, P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation, 1994, 90, 1669-1678.
8. Arbustini, E.; Gavazzi, A.; Dal Bello, B.; Morbini, P.; Campana, C.; Diegli, M.; Grasso, M.; Fasani, R.; Banchieri, N.; Porcu, E.; Pilotto, A.; Ponzetta, M.; Bellin, O.; Lucreziotti, S.; Vigano, M. Ten-year experience with endomyocardial biopsy in myocarditis presenting with congestive heart failure: frequency, pathologic characteristics, treatment and follow-up. G. Ital. Cardiol., 1997, 27, 209-223.
9. Jeziorska, M.; McCollum, C.; Woolley, D.E. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J. Pathol., 1997, 182, 115-122.
10. Businaro, R.; Digregorio, M.; Rigano, R.; Profumo, E.; Buttari, B.; Leone, S.; Salvati, B.; Capoano, R.; D'Amati, G.; Fumagalli, L. Morphological analysis of cell subpopulations within carotid atherosclerotic plaques. Ital. J. Anat. Embryol., 2005, 110, 109-115.
11. Pomerance, A. Peri-arterial mast cells in coronary atheroma and thrombosis. J. Pathol. Bacteriol., 1958, 76, 55-70.
12. Bankl, H.C.; Valent, P. Mast cells, thrombosis, and fibrinolysis. Thromb. Res., 2002, 105, 359-365.
13. Sundberg, M. On the mast cells in the human vascular wall. Acta Pathol. Micorbiol. Immunol. Scand., 1955, 107 (Suppl.), 7-81.
14. Dvorak, A.M. Mast cell degranulation in human hearts. N. Engl. J. Med., 1986, 315, 969-970.
15. Marone, G.; de Cresccnzo, G.; Adt, M.; Patella, V.; Arbustini, E.; Genovese, A. Immunological characterization and functional importance of human heart mast cells. Immunopharmacol., 15, 31, 1-18.
16. Blair, R.J.; Meng, H.; Marchese, M.J.; Ren, S.; Schwartz, L.B.; Tonnesen, M.G.; Gruber, B.L. Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. J. Clin. Invest., 1997, 99, 2691-2700.
17. Garbuzenko, E.; Nagler, A.; Pickholtz, D.; Gillery, P.; Reich, R.; Maquart, F.-X; Levi-Schaffer, F. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin. Exp. All., 2002, 32, 237-246.
18. Knoflach, M.; Kiechl, S.; Mayr, A.; Willeit, J.; Poewe, W.; Wick G. Allergic rhinitis, asthma, and atherosclerosis in the Bruneck and ARMY studies. Arch. Intern. Med., 2005, 165, 2521-2526.
19. Criqui, M.H.; Lee, ER.; Hamburger, R.N.; Klauber, M.R.; Coughlin, S.S. IgE and cardiovascular disease: results from a population-based study. Am. J. Med., 1987, 82, 964-968.
20. Langer, R.D.; Criqui, M.H.; Feigelson, H.S.; McCann, T.J.; Hamburger, R.N. IgE predicts future nonfatal myocardial infarction in men. J. Clin. Epidemiol., 1996, 49, 203-209.
21. Enright, P.L.; Ward, B.J.; Tracy, R.P.; Lasser, E.C. Asthma and its association with cardiovascular disease in the elderly: the Cardiovascular Health Study Research Group. J. Asthma., 1996, 33, 45-53.
22. Hospers, J.J.; Rijcken, B.; Shouten, J.P.; Postma, D.S.; Weiss, S.T. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am. J. Epidemiol., 1999, 150, 482-491.
23. Dwyer, J.H.; Allayee, H.; Dwyer, K.M.; Fan, J.; Wu, H.; Mar, R.; Lusis, A.J.; Mehrabian, M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New Engl. J. Med., 2004, 350, 29-37.
24. Helgadottir, A.; Manolescu, A.; Thorleifisson, G.; Gretarsdottir, S.; Jonsdottir, H.; Thorsteinsdottir, U.; Samiani, N.J.; Gudmundsson, G.; Grant; S.F.A.; Thorgeirsson, G.; Sveinbjornsdottir, S.; Valdimarsson, E.M.; Matthiasson, S.E.; Johannsson, H.; Gudmundsdottir, O.; Gurney, M.E.; Sainz, J.; 'Thorhallsdottir, M.; Andresdottir, M.; Frigge, M.L.; Topol, E.J.; Kong, A.; Gudnason, V.; Hakonarson, H.; Gulcher, J.R.; Stefansson, K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genet., 2004, 36, 233-239.
25. Godeny, E.K.; Sprague, E.A.; Schwartz, C.J.; Gauntt, C.J. Cox-sackievirus group B replication in cultured fetal baboon aortic smooth muscle cells. J. Med. Virol., 1986, 20, 135-149.
26. Roivainen, M. Enteroviruses and myocardial infarction. Am. Heart J., 1999, 138, S479-S483.
27. Kwon, T.W.; do Kim, K.; Ye, J.S.; Lee, W.J.; Moon, M.S.; Joo, C.H.; Lee, H.; Kim, Y.K. Detection of enterovirus, cytomegalovirus, and Chlamydia pneumoniae in atheromas. J. Microbiol., 2004, 42, 299-304.
28. Feldman, A.M.; McNamara, D. Myocarditis. N. Engl. J. Med., 2000, 343, 1388-1398.
29. Fairweather, D.; Rose, N.R. Models of coxsackievirus B3-induced myocarditis: recent advances. Drug Discov. Today: Dis. Models, 2004, 1, 381-386.
30. Fairweather, D.; Rose, N.R. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods, 2007, 41, 119-122.
31. Afanasyeva, M.; Georgakopoulos, D.; Fairweather, D.; Caturegli, P.; Kass, D.A.; Rose, N.R. A novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-γ knockout mice. Circulation, 2004, 110, 2910-2917.
32. Fairweather, D.; Frisancho-Kiss, S.; Yusung, S.A.; Barrett, M.A.; Gatewood, S.J.L.; Davis, S.E.; Njoku, D.B.; Rose, N.R. IFN-γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokincs TGF-β, IL-1β, and IL-4 in the heart. Am. J. Pathol., 2004, 165, 1883-1894.
33. + T cells in IFN-γ knockout mice is associated with progression of myocarditis to heart failure. Proc. Natl. Acad. Sci. USA, 2005, 102, 180-185.
34. Fairweather, D.; Rose, N.R. Inflammatory heart disease: a role for cytokines. Lupus, 2005, 14, 646-651.
35. Fairweather, D.; Kaya, Z.; Shellam, G.R.; Lawson, C.M.; Rose, N.R. From infection to autoimmunity. J. Autoimm., 2001, 16, 175-186.
36. Fairweather, D.; Yusung, S.; Frisancho(-Kiss), S.; Barrett, M.; Gatewood, S.; Steele, R.; Rose, N.R. IL-12Rβ1 and TLR4 increase IL-1β and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol., 2003, 170, 4731-4737.
37. Frisancho-Kiss, S.; Nyland, J.F.; Davis, S.E.; Frisancbo, J.A.; Barrett, M.A.; Rose, N.R.; Fairweather, D. Sex differences in cox-sackievirus B3-induced myocarditis: IL-12Rβ1 signaling and IFN-γ increase inflammation in males independent from STAT4. Brain Res., 2006, 1126, 139-147.
38. Frisancho-Kiss, S.; Davis, S.E.; Nyland, J.F.; Frisancho, J.A.; Cihakova, D.; Rose, N.R.; Fairweather, D. Cutting Edge: Cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol., 2007, 178, 6710-6714.
39. Dec, G.W. In Myocarditis: From Bench to Bedside; L.T. Cooper, Jr., Ed.; Humana Press: Totowa, New Jersey, 2003; pp., 157-281.
40. Liu, P.Y.; Death, A.K.; Handelsman, D.J. Androgens and cardiovascular disease. Endocrine Rev., 2003, 24, 313-340.
41. American Heart Association. Heart Disease & Stroke Statistics-2006 Update, 2006, www.americanheart.org.
42. Neumann, D.A; Burek, C.L.; Baughman, K.L.; Rose, N,R.; Herskowitz, A. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J. Am. Coll. Cardiol., 1990, 16, 839-846.
43. Neumann, D.A.; Rose, N.R.; Ansari, A.A.; Herskowitz, A. Induction of multiple heart autoantibodies in mice with coxsackievirus B3- and cardiac myosin-induced autoimmune myocarditis. J. Immunol, 1994, 152, 343-350.
44. Kaya, Z.; Afanasyeva, M.; Wang, Y.; Dohmen, K.M.; Schlichting, J.; Tretter, T.; Fairweather, D.; Holers, V.M.; Rose, N.R. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nature Immunol., 2001, 2, 739-745.
45. Fairweather, D.; Frisancho-Kiss, S.; Yusung, S.A.; Barrett, M.A.; Davis, S.E.; Steele, R.A.; Gatewood, S.J.L.; Rose, N.R. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-γ and macrophage and neutrophil populations in the heart. J. Immunol., 2005, 174, 261-269.
46. Fairweather, D.; Frisancho-Kiss, S.; Rose, N.R. Viruses as adjuvants for autoimmunity: evidence from coxsackievirus-induced myocarditis. Rev. Med. Virol., 2005, 15, 17-27.
47. Fairweather, D.; Frisancho-Kiss, S.; Njoku, D.B.; Nyland, J.F.; Kaya, Z.; Yusung, S.A.; Davis, S.E.; Frisancho, J.A.; Barrett, M.A.; Rose, N.R. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis and heart failure by increasing macrophages, IL-1β and immune complex deposition in the heart. J. Immunol., 2006, 176, 3516-3524.
48. Dorner, A.; Grunert, H P.; Lindig, V.; Chandrasekharan, K.; Fechner, H.; Knowlton, K.U.; Isik, A.; Pauschinger, M.; Zeichhardt, H.; Schultheiss, H.-P. Treatment of coxsackievirus-B3 -infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury. J. Mol. Med., 2006, 84, 842-851.
49. Lane, J.R.; Neumann, D.A.; LaFond-Walker, A.; Herskowitz, A.; Rose, N.R. LPS promotes CB3-induced myocarditis in resistant B10. A mice. Cell. Immunol., 1991, 136, 219-233.
50. Lane, J.R.; Neumann, D.A.; LaFond-Walker, A.; Herskowitz, A.; Rose, N.R. Interleukin 1 or tumor necrosis factor can promote coxsackievirus B3-induced myocarditis in resistant B10A mice. J. Exp. Med., 1992, 175, 1123-1129.
51. Huber, S.A.; Polgar, J.; Schultheiss, P.; Schwimmbeck, P. Augmentation of pathogenesis of coxsackievirus infections in mice by exogenous administration of interleukin-1 and interleukin-2. J. Virol., 1994, 68, 195-206.
52. Lenzo, J.C.; Fairweather, D.; Shellam, G.R.; Lawson, C.M. Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with lipopolysaccharide and tumor necrosis factor. Cell. Immunol., 2001, 213, 52-61.
53. Yusuf, S.; Reddy, S.; Ounpuu, S.; Anand, S. Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation, 2001, 104, 2746-2753.
54. Drory, Y.; Turetz, Y.; Hiss, Y.; Lev, B.; Fisman, E.Z.; Pines, A.; Kramer, M.R. Sudden unexpected death in persons less than 40 years of age. Am. J. Cardiol., 1991, 68, 1388-1392.
55. Fairweather, D.; Rose, N.R. Women and autoinimune diseases. Emerg. Infect. Dis., 2004, 10, 2005-2011.
56. Tangirala, R.K.; Rubin, E.M.; Palinski, W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res., 1995, 36, 2320-2328.
57. Burnett, M.S.; Gaydos, C.A.; Madico, G.E.; Glad, S.M.; Paigen, B.; Quinn, T.C.; Epstein, S.E. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J. Infect. Dis., 2001, 183, 226-231.
58. Bjorkbacka, H.; Kunjathoor, V.V.; Moore, K.J.; Koehn, S.; Ordija, C.M.; Lee, M.A.; Means, T.; Halmen, K.; Luster, A.D.; Golenbock, D.T.; Freeman, M.W. Reduced atherosclerosis in MyD88-null mice links elevated scrum cholesterol levels to activation of innate immulity signaling pathways. Nature Med., 2004, 10, 416-421.
59. Michelsen, K.S.; Wong, M.H.; Shah, P.K.; Zhang, W.; Yano, J.; Doherty, T.M.; Akira, S.; Rajavashisth, T.B.; Arditi, M. Lack of Toll-like receptor 4 or mycloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA, 2004, 101, 10679-10684.
60. Whitman, S.C.; Ravisankar, P.; Daugherty, A. Interleukin-18 enhances atherosclerosis in apolipoprotein E-/- mice through release of interferon-γ. Circ. Res., 2002, 90, e34-e38.
61. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Aterioscler. Thromb. Vase. Biol., 2003, 23, 656-660.
62. Gupta, S.; Pablo, A.M.; Jiang, X.-C.; Wang, N.; Tall, A.R.; Schindler, C. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest., 1997, 99, 2752-2761.
63. Whitman, S.C.; Ravisankar, P.; Daugherty, A. IFN-γ deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/ -mice. J. Interferon Cytok. Res., 2002, 22, 661-670.
64. Fairweather, D.; Frisancho-Kiss, S.; Gatewood, S.; Njoku, D.; Steele, R.; Barrett, M.; Rose, N.R. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity, 2004, 37, 131-145.
65. Davenport, P.; Tipping, P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol., 2003, 163, 1117-1125.
66. Walch, L.; Massade, L.; Dufilho, M.; Brunet, A.; Rendu, F. Proatherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis, 2006, 187, 285-291.
67. Medzhitov, R.; Janeway, C.A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science, 2002, 296, 298-300.
68. Fingberg, R.W.; Kurt-Jones, E.A. Viruses and Toll-like receptors. Microb. Infect., 2004, 6, 1356-1360.
69. + T lymphocytes. Eur. J. Immunol., 1996, 26, 2517-2528.
70. Malaviya, R.; Twesten, N.J.; Ross, E.A.; Abraham, S.N.; Pfeifer, J.D. Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J. Immunol., 1996, 156, 1490-1496.
71. Mekori, Y.A.; Metcalfe, D.D. Mast cell-T cell interactions. J. Allergy Clin. Immunol., 1999, 104, 517-523.
72. Christy, A.L.; Brown, M.A. The multitasking mast cell: positive and negative roles in the progression of autoimmunity. J. Immunol., 2007, 179, 2673-2679.
73. Jawdat, D.M.; Rowden, G.; Marshall, J.S. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol., 2006, 177, 1755-1762.
74. Fairweather, D.; Rose, N.R. Immunopathogenesis of autoimmune disease. In Immunotoxicology and Immunopharmacology; Luebke, R., House, R., Kimber, I. Eds.; CRC Press: Boca Raton, FL, 2007; 3rd Ed., pp., 423-436.
75. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T cell immunity. Nature Rev. Immunol., 2004, 4, 336-347.
76. Nelson, B.H. IL-2, regulatory T cells, and tolerance. J. Immunol., 2004, 172, 3983-3988.
77. Tivol, E.A.; Borriello, F.; Schweitzer, A.N.; Lynch, W.P.; Bluestone, J.A.; Sharpe, A.H. Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 1995, 3, 541-547.
78. Meyers, J.H.; Sabatos, C.A.; Chakravarti, S.; Kuchroo, V.K. The TIM gene family regulates autoimmune and allergic diseases. TRENDS Mol. Med., 2005, 11, 362-369.
79. Monney, L.; Sabatos, C.A.; Gaglia, J.L.; Ryu, A.; Waldner, H.; Chernova, T.; Manning, S.; Greenfield, E.A.; Coyle, A.J.; Sobel, R.A.; Freeman, G.J.; Kuchroo, V.J. Th1-specific cell surface protein Tim-3 regulates macrophage activation and the severity of autoimmune disease. Nature, 2002, 415, 536-541.
80. Sabatos, C.A.; Chakravarti, S.; Cha, E.; Schubart, A.; Sanchez-Fueyo, A.; Zheng, X.X., Coyle, A.J.; Strom, T.B.; Freeman, G.J.; Kuchroo, V.J. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nature Immunol., 2003, 4, 1102-1110.
81. Sanchez-Fueyo, A.; Tian, J.; Picarella, D.; Domenig, C.; Zheng, X.X.; Sabatos, C.A.; Manlongat, N.; Bender, O.; Kamradt, T.; Kuchroo, V.J.; Gutierrez-Ramos, J.-C.; Coyle, A.J.; Strom, T.B. Tim-3 inhibits T helper type 1-mediated auto- and alloimmume responses and promotes immunologic tolerance. Nature Immunol., 2003, 4, 1093-1101.
82. Frisancho-Kiss, S.; Nyland, J.F.; Davis, S.E.; Barrett, M.A.; Gatewood, S.J.L.; Njoku, D.B.; Cibakova, D.; Silbergeld, EX.; Rose, N.R.; Fairweather, D. Cutting Edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA4 during innate immunity. J. Immunol., 2006, 176, 6411-6415.
83. Manabe, I.; Shindo, T.; Nagai, R. Gene expression in fibroblasts and fibrosis: Involvement in cardiac hypertrophy. Cirr. Res., 2002, 91, 1103-1113.
84. Schultz, J.E.J.; Witt, S.A.; Glascock, B.J.; Nieman, M.L.; Reiser, P.J.; Nix, S.L.; Kimball, T.R.; Doetschman, T. TGF-β1 mediates the hypertrophic cardiomyocytes growth induced by angiotensin II. J. Clin. Invest., 2002, 109, 787-796.
85. Kuwahara, F.; Kai, H.; Tokuda, K.; Kai, M.; Takeshita, A.; Egashira, K.; Imaizumi, T. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation, 2002, 106, 130-135.
86. Bouzegrhane, F.; Thibault, G. Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc. Res., 2002, 53, 304-312.
87. 1, receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ. Res., 2002, 91, 1119-1126.
88. Eickelberg, O.; Pansky, A.; Koehler, E.; Bihl, M.; Tamm, M.; Hildebrand, P.; Perruchoud, A.P.; Kashgarian, M.; Roth, M. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporin A in lung fibroblasts. FASEB J., 2001, 15, 797-806.
89. Oldroyd, S.D.; Thomas, G.L.; Gabbiani, G.; El Nahas, A.M. Interferon-γ inhibits experimental renal fibrosis. Kidney International, 1999, 56, 2116-2127.
90. Ahdieh, M.; Vandenbos, T.; Youakin, A. Lung epithelial barrier function and wound heating are decreased by IL4 and IL-13 and enhanced by IFN-γ. Am. J. Physiol. Cell. Physiol., 2001, 281, C2029-C2038.
91. Hara, M.; Ono, K.; Hwang, M.W.; Iwasaki, A.; Okada, M.; Nakatani, K.; Sasayama, S.; Matsumori, A. Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med., 2002, 195, 375-381.
92. Hawkins, R.A.; Claman, H.N.; Clark, R.A.; Steigerwald, J.C. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann. Intern. Med., 1985, 102, 182-186.
93. Secor, V.H.; Secor, W.E.; Gutekunst, C.A.; Brown, M.A. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med., 2000, 191, 813-821.
94. Woolley, D.E.; Tetlow, L.C. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res., 2000, 2, 65-74.
95. Lorentz, A.; Schuppan, D.; Gebert, A.; Manns, M.P.; Bischoff, S.C. Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood 2002, 99, 966-972.
96. Subramanian, N.; Bray, M.A. Interleukin 1 releases histamine from human basophils and mast cells in vitro. J. Immunol., 1987, 138, 271-275.
97. Strait, R.T.; Morris, S.C.; Smiley, K.; Urban, J.F. Jr.; Finkelman, F.D. IL-4 exacerbates anaphylaxis. J. Immunol., 2003, 170, 3835-3942.
98. Cairns, J.A.; Walls, A.F. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest., 1997, 99, 1313-1321.
99. Boyce, J.A. Mast cells: beyond IgE. J. Allergy Clin. Immunol., 2003, 111, 24-32.
100. Prussin, C.; Metcalfe, D.D. IgE, mast cells, basophils, and cosinophils. J. Allergy Clin. Immunol., 2003, 111, S486-S494.
101. Musio, S.; Gallo, B.; Scabeni, S.; Lapilla, M.; Poliani, P.L.; Materese, G.; Ohtsu, H.; Gallo, S.J.; Mantegazza, R.; Steinman, L.; Pedotti, R. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. J. Immunol., 2006, 176, 17-26.
102. Zhang, M.; Venable, J.D.; Thurmond, R.L. The histamine IL receptor in autoimmune disease. Expert Opin. Investig. Drugs, 2006, 15, 1443-1452.
103. 1 receptor and iNOS by RT-PCR in autoimmune myocarditis with special reference to changes in heart contractility. Intern. J. Cardiol., 2000, 76, 165-172.
104. Kim, J.; Ogai, A.; Nakatani, S.; Hashimura, K.; Kanzaki, H.; Komamura, K.; Asakura, M.; Asanuma, H.; Kitamura, S.; Tomoike, H.; Kitakaze, M. Impact of blockade of bistamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J. Am. Coll. Cardiol., 2006, 48, 1378-1384.
105. Kaya, Z.; Dohmen, K.M.; Wang, Y.; Schlichting, J.; Afanasyeva, M.; Leuschner, F.; Rose, N.R. Cutting Edge: A critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J. Immunol., 2002, 15, 1552-1556.
106. Palaniyandi, S.S.; Watanabe, K.; Ma, M.; Tachikawa, H.; Kodama, M.; Aizawa, Y. Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. Eur. J. Immunol., 2004, 34, 3508-3515.
107. Kitaura-Inenaga, K.; Hara, M.; Higuchi, K.; Yamamoto, K.; Tamaki, A.; Ono, K.; Nakano, A.; Kinoshita, M.; Sasayama, S.; Matsumori, A. Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. Circ. J., 2003, 67, 881-884.
108. Doggrell, S.A.; Wanstall, J.C. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can. J. Physiol. Pharmacol., 2005, 83, 123-130.
109. Gunasinghe, S.K.; Ikonomidis, J.; Spinale, F.G. Contributory role of matrix metalloproteinases in cardiovascular remodeling. Curr. Drug Targets- Cardiov. Haematol. Disorders, 2001, 1, 75-91.
110. Ram, M.; Sherer, Y.; Shoenfeld, Y. Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol., 2006, 26, 299-307.
111. Filipiak, K.J.; Tarchalska-Krynska, B.; Opolski, G.; Rdzanck, A.; Kochman, J.; Kosior, D.A. Czlonkowski, A. Tryptase levels in patients after acute coronary syndromes: the potential new marker of an unstable plaque? Clin. Cardiol., 2003, 26, 366-372.
112. Deliargyris, E.N.; Upadhya, B.; Sane, D.C.; Dehmer, G.J.; Pye, J.; Smith, S.C. Jr.; Boucher, W.S.; Theoharides, T.C. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis, 2005, 178, 381-386.
113. Isozaki, Y.; Yoshida, N.; Kuroda, M.; Handa, O.; Takagi, T.; Kokura, S.; Ichikawa, H.; Naito, Y.; Okanoue, T.; Yoshikawa, T. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis. Scand. J. Gastroenterol., 2006, 41, 944-953.
114. Haberal, I.; Corey, J.P. The role of leukotrienes in nasal allergy. Otolaryngol. Head Neck Surg., 2003, 129, 274-279.
115. Radmark, O., 5-Lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1140-1142.
116. Perez Leiros, C.; Sterin-Borda, L.; Borda, E.S. Lymphocyte infiltration induces dysfunction in autoimmune myocarditis: role of SRS-A. J. Mol. Cell. Cardiol. 1988, 20, 149-158.
117. Aiello, R.J.; Bourassa, P.A.; Lindsey, S.; Weng, W.; Freeman, A.; Showell, H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 443-449.
118. Dwyer, J.H.; Allayee, H.; Dwyer, K.M.; Fan, J.; Wu, H.; Mar, R.; Lusis, A.J.; Mehrabian, M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New Engl. J. Med., 2004, 350, 29-37.
119. + T regulatory type 1 response by cyclooxygenase -2-overexpressing glioma. J. Immunol., 2004, 173, 4352-4359.
120. Gilde, A.J.; Fruchart, J.C.; Staels, B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. J. Am. Coll. Cardiol., 2006, 48, A24-A32.
121. Takahashi, T.; Zhu, S.J.; Sumino, H.; Saegusa, S.; Nakahashi, T.; Iwai, K.; Morimoto, S.; Kanda, T. Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci., 2005, 78, 195-204.
122. Suzuki, J.I.; Ogawa, M.; Futamatsu, H.; Kosuge, H.; Tanaka, H.; Isobe, M. A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J. Mol. Cell. Cardiol., 2006, 40, 688-695.
123. Mamdani, M.; Juurlink, D.N.; Lee, D.S.; Rochon, P.A.; Kopp, A.; Naglie, G.; Austin, P.C.; Laupacis, A.; Stukel, T.A. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet, 2004, 363, 1751-1756.
124. Psaty, B.M.; Furberg, C.D. COX-2 inhibitors- lessons in drug safety. New Engl. J. Med., 2005, 352, 1133-1135.
125. Das, U.N. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J., 2006, 1, 420-439.
126. Tran, H.A.; Anand, S.S.; Hankey, G.J.; Eikelboom, J.W. Aspirin resistance. Thromb. Res., 2007, 120, 337-346.
127. Sanchez de Miguel, L.; de Frutos, T.; Gonzalez-Fernandez, F.; del Pozo, V.; Lahoz, C.; Jimenez, A.; Rico, L.; Garcia, R.; Accituno, E.; Millas, I.; Gomez, J.; Farre, J.; Casado, S.; Lopez-Farre, A. Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-α release by cultured smooth muscle cells. Eur. J. Clin. Invest., 1999, 29, 93-99.
128. Huang, C.Y.; Wu, T.C.; Lin, W.T.; Leu, H.B.; Lin, C.P.; Lin, S.J.; Chen, J.W. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur. J. Clin. Invest., 2006, 36, 76-84.
129. Liu, W.; Li, W.M.; Gao, C.; Sun, N.L. Effects of atorvastatin on the Th1/ Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J. Autoimmun., 2005, 25, 258-263.
130. Li, W.M.; Liu, W.; Gao, C.; Zhou, B.G. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunol. Cell Biol., 2006, 84, 274-280.
131. Sudano, I. Spieker, L.E., Noll, G., Corti, R., Weber, R., Luscher, T.F. Cardiovascular disease in HIV infection. Am. Heart J., 2006, 151, 1147-1155.